Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.33 |
| ▸ | BCR | P11274 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3468563 | 0.82 | MMP3 (0.47) | ESR1MMP3SMN1; SMN2NPC1MAPT | |
| SCHEMBL3469077 | 0.81 | ESR1 (0.43) | ESR1CHEK1MMP9MMP2SMN1; SMN2 | |
| SCHEMBL3075044 | 0.80 | ESR1 (0.50) | ESR1SMN1; SMN2MAPTESR2 | |
| SCHEMBL3468408 | 0.80 | ESR1 (0.56) | ESR1HSD17B10PDE4DAVPR1ASMN1; SMN2 | |
| SCHEMBL3467813 | 0.80 | ESR1 (0.44) | ESR1HSD17B10MMP9MAPTRARB | |
| SCHEMBL3467569 | 0.79 | ESR1 (0.47) | ESR1HSD17B10PDE4DAVPR1ASMN1; SMN2 | |
| SCHEMBL27640751 | 0.79 | ESR1 (0.39) | ESR1HSD17B10ABL1ABCB1BCR | |
| SCHEMBL3468278 | 0.78 | FGFR1 (0.44) | ESR1ABL1ABCB1BCRMMP3 | |
| SCHEMBL3468373 | 0.77 | SLC6A3 (0.49) | ESR1MAPTLTB4R2 | |
| SCHEMBL3628757 | 0.75 | ABL1 (0.54) | ESR1PDK2CHEK1PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007500705-A | — | — | 2007-01-18 | — | — | JP | claimed |
| EP-1667955-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF THE ESTROGEN RECEPTOR | SmithKline Beecham Corporation (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005012220-A9 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORP (US) | 2005-05-19 | — | — | WO | claimed |
| WO-2005012220-A2 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | claimed |
| US-7799828-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | GLAXOSMITHKLINE LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799828-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | GLAXOSMITHKLINE LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799828-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | GLAXOSMITHKLINE LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090253659-A1 | Cycloalkylidene Compounds As Modulators of Estrogen Receptor | GLAXOSMITHKLINE LLC | 2009-10-08 | — | — | US | disclosed |
| US-20090253659-A1 | Cycloalkylidene Compounds As Modulators of Estrogen Receptor | GLAXOSMITHKLINE LLC | 2009-10-08 | — | — | US | disclosed |
| US-20090253659-A1 | Cycloalkylidene Compounds As Modulators of Estrogen Receptor | GLAXOSMITHKLINE LLC | 2009-10-08 | — | — | US | disclosed |
| US-7569601-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569601-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-7560589-B2 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070213348-A1 | Chemical Compounds | BRITTON JONATHAN E | 2007-09-13 | — | — | US | disclosed |
| US-20070213348-A1 | Chemical Compounds | BRITTON JONATHAN E | 2007-09-13 | — | — | US | disclosed |
| US-20070213348-A1 | Chemical Compounds | BRITTON JONATHAN E | 2007-09-13 | — | — | US | disclosed |
| US-20070155839-A1 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155839-A1 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155839-A1 | Cycloalkylidene compounds as modulators of estrogen receptor | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| WO-2005012220-A9 | CYCLOALKYLIDENE COMPOUNDS AS MODULATORS OF ESTROGEN RECEPTOR | SMITHKLINE BEECHAM CORP (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155839-A1 | Cycloalkylidene compounds as modulators of estrogen receptor | ESR2, GPER1, ESRRG | ESR1 4/4885PDK2 2326/4885CHEK1 3123/4885 |
| US-20090253659-A1 | Cycloalkylidene Compounds As Modulators of Estrogen Receptor | ESR2, GPER1, ESRRG | ESR1 4/4885PDK2 2326/4885CHEK1 3123/4885 |
| US-20070213348-A1 | Chemical Compounds | GPER1, ESR2, ESR1 | ESR1 3/4885PDK2 1239/4885CHEK1 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.